Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

Alvar Agustí, Luis de Teresa, Wilfried De Backer, Michael T. Zvarich, Nicholas Locantore, Neil Barnes, Jean Bourbeau, Courtney Crim
European Respiratory Journal 2013; DOI: 10.1183/09031936.00054213
Alvar Agustí
*Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; and FISIB, CIBER Enfermedades Respiratorias (CIBERES), Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alvar.agusti@clinic.ub.es
Luis de Teresa
¶Clinica Mediterranea de Neurociencias, Alicante, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilfried De Backer
#University of Antwerp, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael T. Zvarich
+GlaxoSmithKline, Research Triangle Park, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Locantore
+GlaxoSmithKline, Research Triangle Park, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Barnes
§Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Bourbeau
fMcGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney Crim
+GlaxoSmithKline, Research Triangle Park, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Fluticasone furoate/vilanterol trifenatate (FF/VI) is a once-daily (OD) inhaled corticosteroid/long-acting β2-agonist combination in development for chronic obstructive pulmonary disease (COPD) treatment. We compared the efficacy and safety of FF/VI versus fluticasone propionate/salmeterol (FP/SAL) twice-daily (BD) over 12 weeks.

Moderate to very severe COPD patients received FF/VI 100/25 μg OD in the morning (N=266) or FP/SAL 500/50 μg BD (N=262). Primary endpoint: change from baseline in 0–24 h weighted mean forced expiratory volume in 1 s (wmFEV1) at 12 weeks. Additional endpoints included: time to 100 mL improvement from baseline on day 1; change from baseline in St George's Respiratory Questionnaire (SGRQ). Safety was also assessed.

wmFEV1 (mean, 130 mL) was greater and time to 100 mL improvement shorter (median, 16 min) with FF/VI than FP/SAL (mean [wm], 108 mL; median, 28 min). Health status (SGRQ total score) improved in both groups (FF/VI, –4.3 units; FP/SAL, –3.0 units). Differences between treatments were not statistically significant. Six patients in the FF/VI (2%) and 3 in the FP/SAL (1%) arm experienced serious adverse events, none of which were considered to be drug-related.

Improvements in lung function and health status were not significantly different between FF/VI 100/25 μg OD and FP/SAL 500/50 μg BD; there was no apparent differentiation between the safety profiles of either therapy.

  • Chronic bronchitis
  • chronic obstructive pulmonary disease
  • emphysema
  • inhaled corticosteroid
  • long-acting β2 agonist
  • lung function
  • ERS
Next
Back to top
Vol 57 Issue 1 Table of Contents
European Respiratory Journal: 57 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Alvar Agustí, Luis de Teresa, Wilfried De Backer, Michael T. Zvarich, Nicholas Locantore, Neil Barnes, Jean Bourbeau, Courtney Crim
European Respiratory Journal Jan 2013, erj00542-2013; DOI: 10.1183/09031936.00054213

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Alvar Agustí, Luis de Teresa, Wilfried De Backer, Michael T. Zvarich, Nicholas Locantore, Neil Barnes, Jean Bourbeau, Courtney Crim
European Respiratory Journal Jan 2013, erj00542-2013; DOI: 10.1183/09031936.00054213
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary pharmacology and therapeutics
  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: A randomised clinical trial
  • Lung transplantation for sarcoidosis: outcome and prognostic factors
  • Chronic Pulmonary Aspergillosis: Prevalence, favouring pulmonary diseases and prognosis
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society